Placebo Comparator: Randomized pectin diet: UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin
Randomized B-fructan diet: UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan
Personalized pectin diet: UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline
Personalized B-fructan diet: UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
Study summary
This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.
Eligibility
Sex
ALL
Min age
6 Years
Max age
39 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Children (age 6-17) or young adults (age 18-39).
* Known or suspected UC or IBDU \[there will be 2 control group: non-IBD (undergoing colonoscopy but found not to have IBD; and healthy (no GI symptoms, so not required to have colonoscopy; could be family members)\]
* For UC: Remission-mild-moderate disease: Mayo score \<10
* Clinical indication for sedated colonoscopy
* Disease location: E2-E4
* Stable treatment (not on steroids; biologics or immunomodulator not changed in last month)
* High likelihood that patients will be able to collect all samples and provide all data
Exclusion Criteria:
* Use of antibiotics for a week or more over the last 3 months
* Use of probiotics or prebiotics at pharmacological doses (adding fibre sources to food or probiotics in yogurt, for example, are allowed)
* History of abdominal surgery, including appendectomy
* Documented enteric infection during the 3 months prior to endoscopy
* Presence of non-IBD bowel conditions (e.g., celiac), anatomical or mucosal abnormalities, motility disorder
* Presence of a systemic disease requiring treatment (cancer, ischemic heart disease, kidney failure, etc)
* Proctitis (E1)
* Systemic steroids (above 10 mg/day of Prednisone)
* Topical therapy within 1 week of endoscopy
* Recent change in IBD treatment (started biologics or IM over the last month)
* Pregnancy or planning to become pregnant during the study
* Inability to understand or sign the consent
Primary outcome measure(s)
Diet tolerability — 4 weeks Percentage of patients able to tolerate a personalized fiber diet provided by a dietitian will be evaluated at week 4 by measure of patient symptom score (PROMIS questionnaire) and willingness to continue adherence to diet advice provided.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.